pharmacokineticsanddispositionofanlotinibanoraltyrosinekinaseinhibitorinexperimentalanimalspecies
文献类型：期刊论文
| 作者 | Zhong Chenchun; Chen Feng; Yang Junling ; Jia Weiwei; Li Li; Cheng Chen; Du Feifei; Zhang Suping; Xie Chengying; Zhang Nating
|
| 刊名 | actapharmacologicasinica
 |
| 出版日期 | 2018 |
| 卷号 | 039期号:006页码:1048 |
| 关键词 | 酷氨酸 布置 动物种类 试验性 血浆蛋白质 相互作用 新陈代谢 CYP3A |
| ISSN号 | 1671-4083 |
| 英文摘要 | Anlotinib is a new oral tyrosine kinase inhibitor; this study was designed to characterize its pharmacokinetics and disposition. Anlotinib was evaluated in rats, tumor-bearing mice, and dogs and also assessed in vitro to characterize its pharmacokinetics and disposition and drug interaction potential. Samples were analyzed by liquid chromatography/mass spectrometry. Anlotinib, having good membrane permeability, was rapidly absorbed with oral bioavailability of 28%-58% in rats and 41%-77% in dogs. Terminal half-life of anlotinib in dogs （22.8＋11.0 h） was longer than that in rats （5.1±1.6 h）. This difference appeared to be mainly associated with an interspecies difference in total plasma clearance （rats, 5.35±1.31 L·h-1·kg-1; dogs, 0.40±0.06 L·h-1·kg-1）. Cytochrome P450-mediated metabolism was probably the major elimination pathway. Human CYP3A had the greatest metabolic capability with other human P450s playing minor roles. Anlotinib exhibited large apparent volumes of distribution in rats （27.6±3.1 L/kg） and dogs （6.6±2.5 L/kg） and was highly bound in rat （97%）, dog （96%）, and human plasma （93%）. In human plasma, anlotinib was predominantly bound to albumin and lipoproteins, rather than to α1-acid glycoprotein or y-globulins. Concentrations of anlotinib in various tissue homogenates of rat and in those of tumor-bearing mouse were significantly higher than the associated plasma concentrations. Anlotinib exhibited limited in vitro potency to inhibit many human P450s, UDP-glucuronosyltransferases, and transporters, except for CYP3A4 and CYP2C9 （in vitro half maximum inhibitory concentrations, 〈1 μmol/L）. Based on early reported human pharmacokinetics, drug interaction indices were 0.16 for CYP3A4 and 0.02 for CYP2C9, suggesting that anlotinib had a low propensity to precipitate drug interactions on these enzymes. Anlotinib exhibits many pharmacokinetic characteristics similar to other tyrosine kinase inhibitors, except for terminal half-life, interactions with drug metabolizing enzymes and transporters, and plasma protein binding. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/285770]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 中国科学院上海药物研究所 |
| 推荐引用方式 GB/T 7714 | Zhong Chenchun,Chen Feng,Yang Junling,et al. pharmacokineticsanddispositionofanlotinibanoraltyrosinekinaseinhibitorinexperimentalanimalspecies[J]. actapharmacologicasinica,2018,039(006):1048. |
| APA | Zhong Chenchun.,Chen Feng.,Yang Junling.,Jia Weiwei.,Li Li.,...&Li Chuan.(2018).pharmacokineticsanddispositionofanlotinibanoraltyrosinekinaseinhibitorinexperimentalanimalspecies.actapharmacologicasinica,039(006),1048. |
| MLA | Zhong Chenchun,et al."pharmacokineticsanddispositionofanlotinibanoraltyrosinekinaseinhibitorinexperimentalanimalspecies".actapharmacologicasinica 039.006(2018):1048. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。